What's happening
Eli Lilly announced Phase 1b data on May 25, 2026 from its Heart-2 trial of VERVE-102, a gene-editing therapy targeting cardiovascular disease. At the high dose, VERVE-102 reduced LDL cholesterol levels by up to 62% and suppressed PCSK9 — a protein that regulates LDL receptor activity — by up to 88%. Critically, these reductions were sustained for up to 18 months following a single treatment, and no treatment-related serious adverse events were observed across trial participants.
Lilly obtained VERVE-102 through its $1 billion acquisition of Verve Therapeutics in 2025. The therapy is designed as a one-time gene-editing intervention intended to produce durable reductions in LDL cholesterol, a primary risk factor for cardiovascular disease. Following the Phase 1b results, Lilly has announced plans to begin enrolling patients in a Phase 2 clinical study of VERVE-102 by the end of 2026.
Why it matters for markets
The cardiovascular therapeutics market is among the largest in pharmaceuticals, and a durable, one-time gene-editing treatment for LDL reduction would compete in a space currently dominated by daily oral statins and injectable PCSK9 inhibitors. A 62% reduction in LDL-C sustained over 18 months from a single administration represents a clinically meaningful efficacy signal at the Phase 1 stage, though Phase 2 data will be required to establish broader safety and efficacy profiles across larger patient populations.
For Lilly, the $1 billion Verve acquisition now has a tangible clinical milestone attached to it, providing early validation of the deal's strategic rationale. Lilly currently carries a market capitalization of approximately $949.47 billion and reported revenue of $72.25 billion, with a P/E ratio of 37.9 — a valuation that reflects investor expectations of sustained pipeline execution. Positive Phase 1 data in a high-profile therapeutic area such as cardiovascular gene editing reinforces the company's positioning beyond its core GLP-1 and oncology franchises.
The PCSK9 suppression figure of up to 88% is particularly notable given that approved PCSK9 inhibitors such as evolocumab and alirocumab have established the clinical and commercial viability of targeting this pathway. A gene-editing approach that achieves comparable or superior pathway suppression through a single administration, if confirmed in later-stage trials, would represent a structural shift in how cardiovascular risk is managed long-term.
Sectors and assets to watch
Eli Lilly (LLY) is the primary ticker directly affected by this development. With a 52-week range of $623.78 to $1,133.95 and a current price of $1,064.74, the stock trades near the upper end of its annual range. The Phase 1b data and the announced Phase 2 enrollment timeline add a new clinical catalyst to Lilly's pipeline narrative, which has been heavily weighted toward its GLP-1 franchise anchored by Mounjaro (tirzepatide).
Broader cardiovascular gene therapy and gene-editing sectors are also relevant to monitor. Companies with competing or complementary programs in base editing, CRISPR-based cardiovascular therapies, or PCSK9-targeting approaches may face increased competitive benchmarking as VERVE-102 advances. Additionally, established PCSK9 inhibitor franchises held by larger pharmaceutical companies represent a commercial segment that a successful one-time gene therapy could eventually address.
What to watch next
The most immediate milestone to monitor is Lilly's initiation of Phase 2 enrollment for VERVE-102, targeted for before the end of 2026. Phase 2 trial design details — including patient population size, dosing regimen, primary endpoints, and duration — will provide the next layer of data needed to assess the therapy's commercial and clinical trajectory. Investors and analysts will also be watching for any further safety signals as the trial expands to a larger cohort, as well as any regulatory interactions with the FDA regarding the development pathway for a gene-editing cardiovascular therapy.